UniSuper Management Pty Ltd Has $2.51 Million Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

UniSuper Management Pty Ltd raised its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 21.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,783 shares of the medical equipment provider's stock after acquiring an additional 4,213 shares during the period. UniSuper Management Pty Ltd's holdings in Zimmer Biomet were worth $2,512,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. CKW Financial Group boosted its stake in Zimmer Biomet by 11.7% during the 4th quarter. CKW Financial Group now owns 955 shares of the medical equipment provider's stock valued at $101,000 after purchasing an additional 100 shares during the period. Romano Brothers AND Company increased its position in Zimmer Biomet by 1.1% in the 4th quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider's stock valued at $1,000,000 after acquiring an additional 102 shares during the period. Dorsey & Whitney Trust CO LLC raised its stake in Zimmer Biomet by 2.3% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider's stock valued at $485,000 after acquiring an additional 102 shares in the last quarter. M&T Bank Corp boosted its position in Zimmer Biomet by 0.4% during the 4th quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider's stock worth $2,834,000 after acquiring an additional 108 shares during the period. Finally, Dakota Wealth Management grew its stake in shares of Zimmer Biomet by 1.3% in the fourth quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider's stock worth $1,016,000 after purchasing an additional 122 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Remove Ads

Analyst Ratings Changes

ZBH has been the topic of a number of recent analyst reports. JMP Securities restated a "market outperform" rating and set a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. JPMorgan Chase & Co. raised Zimmer Biomet from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Raymond James lowered their price target on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Barclays cut their price objective on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a report on Monday, February 10th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $124.15.

Zimmer Biomet Stock Up 0.1 %

ZBH stock traded up $0.11 during mid-day trading on Thursday, hitting $112.61. The stock had a trading volume of 537,649 shares, compared to its average volume of 1,824,670. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $130.89. The company has a fifty day moving average of $107.35 and a 200 day moving average of $107.18. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $22.42 billion, a price-to-earnings ratio of 25.31, a PEG ratio of 1.95 and a beta of 1.04.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter last year, the firm earned $2.20 EPS. On average, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.85%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's payout ratio is 21.57%.

Insiders Place Their Bets

In other news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This represents a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.70% of the company's stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.